Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort

Mostrar otras versiones (1)

BACKGROUND: Trastuzumab was introduced a decade ago and has improved outcomes for HER2-positive breast cancer. We investigated the factors predictive of pathological complete response (pCR), prognostic factors for disease-free survival (DFS), and interactions between pCR and DFS after neoadjuvant tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamy-Petit, Anne-Sophie, Belin, Lisa, Bonsang-Kitzis, Hélène, Paquet, Caroline, Pierga, Jean-Yves, Lerebours, Florence, Cottu, Paul, Rouzier, Roman, Savignoni, Alexia, Lae, Marick, Reyal, Fabien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716543/
https://www.ncbi.nlm.nih.gov/pubmed/26657653
http://dx.doi.org/10.1038/bjc.2015.426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716543/
https://www.ncbi.nlm.nih.gov/pubmed/26657653
http://dx.doi.org/10.1038/bjc.2015.426

Ejemplares similares